
Research shows that specific antibody patterns in blood can signal the onset of Crohn's disease and ulcerative colitis up to ten years before symptoms appear, offering potential for earlier detection and prevention of inflammatory bowel disease, which affects at least 3.8 million people worldwide.
AI-generated summary
Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects at least 3.8 million people worldwide and is typically diagnosed only after symptoms appear and gut damage has occurred. Current treatments rely on anti-inflammatory and immune-suppressing drugs, but many patients do not respond, and some require surgery. Longstanding inflammation increases bowel cancer risk.
Patterns of antibodies in people’s blood could predict the onset of inflammatory bowel disease (IBD) a decade before diagnosis, according to research that raises hopes for catching the condition early.
Crohn’s disease and ulcerative colitis, the two main forms of IBD, are typically treated only after symptoms appear, when the gut has already been damaged. But scientists found that the immune system sends warning signals up to a decade before diagnosis, paving the way for potentially earlier detection and even prevention.
“For too long we have only been able to treat inflammatory bowel disease once the damage is done, and for many people that is too late,” said Dr Arno Bourgonje at the University Medical Centre Groningen in the Netherlands and the Icahn School of Medicine at Mount Sinai in New York.
“What we have shown is that the disease begins years before symptoms appear, and the immune system leaves warning signs long before diagnosis,” Bourgonje added. “This is not yet a test that can tell someone they will become ill, but it is an important step towards catching the disease earlier and, one day, preventing it.”
At least 3.8 million people worldwide live with IBD, an immune condition that drives chronic inflammation of the digestive tract, causing pain, diarrhoea and fatigue. The exact cause is unknown, but a misfiring immune system, genetics and microbes living in the gut can all contribute.
Treatment relies on anti-inflammatory and immune-suppressing drugs, but many patients do not respond, and a significant number go on to have surgery to remove damaged sections of bowel. Longstanding inflammation also raises the risk of bowel cancer. This has prompted scientists to look for the earlier signs of disease, in the hope of identifying people at risk before damage begins.
Bourgonje and colleagues at Mount Sinai and the Medical University of Vienna ran tests on blood samples taken from US military personnel. They examined 2,000 samples from 500 people, 200 of whom later developed Crohn’s disease, and 200 who went on to develop ulcerative colitis. The remaining 100 developed neither condition.
The blood samples were screened for antibodies that the immune system might have churned out in response to hundreds of thousands of fragments of proteins from bacteria, viruses, food and even the body’s own tissues.
In people who went on to develop Crohn’s disease, antibodies against Epstein-Barr virus, which causes glandular fever, were more common, and the differences were already visible a decade before diagnosis. The signal was strongest in those who later developed more severe, complicated disease, which can narrow the bowel or create abnormal channels.
People who developed ulcerative colitis showed a different pattern, including antibodies against one of the body’s own proteins.
The findings, published in the journal Gut and presented at the United European Gastroenterology meeting in Barcelona, need to be confirmed in other groups of people, and the results show a link rather than proving the infections cause IBD. But the hope is that IBD could eventually follow the path of type 1 diabetes, where a blood test can identify people whose immune systems have begun attacking the pancreas before any symptoms appear, allowing treatment that delays the onset of disease.
James Lindsay, a professor of gastroenterology at Barts Health, who was not involved in the research, said the study provided “important insights into the causes of Crohn’s disease and ulcerative colitis, potentially adding new tools to help identify those at risk of IBD”. But he cautioned that the techniques were “very much a research tool” and not yet ready for the clinic.
Marianne Radcliffe, the chief executive of Crohn’s & Colitis UK, a national patient charity, said: “For people affected by Crohn’s and colitis, research like this is an important step forward. Every new insight helps build a clearer understanding of how these conditions develop, including the changes that may occur years before symptoms appear.”
AI outlook — possibilities, not facts
Antibody-based screening could be developed into a clinical test for identifying people at risk of IBD before symptoms appear
Possible · Within years
Early detection of IBD risk could lead to preventive treatments that delay or prevent disease onset
Possible · Within years

Kenya's Health Ministry confirmed its eighth Ebola case, a patient attendant linked to the country's first case. Meanwhile, DRC health officials reported the outbreak spreading to its eighth province, Nord-Ubangi.

High school students in Michigan saved their physical education teacher's life using CPR and an AED, underscoring the vital role of school-based resuscitation training as 43 U.S. states now require CPR education for graduation.

Sudan's ongoing civil war has devastated the healthcare system and economy, leaving chronic illness patients like Hasanat al-Rashid, Fatima Adam, and Huda Mahmoud struggling to afford and access vital medications amid soaring inflation.

Controversial Australian natural remedy proponent Barbara O'Neill is holding wellness retreats in the UK, advising attendees to reject mainstream medical treatments, stop taking prescribed medications for conditions like diabetes and thyroid issues, and use unscientific remedies.

Occupied West Bank's healthcare system collapses as Beit Jala Government Hospital faces severe drug shortages, half-salaries for staff, and restrictive Israeli checkpoints that block patients and medical supplies.

Multiple NHS trusts across England are rejecting Palantir's £330m patient data platform, citing superior local alternatives and limited added benefit, as the government faces a decision on contract break clauses amid ongoing controversy.